Literature DB >> 24671239

Correlation between glucose uptake and membrane potential in Leishmania parasites isolated from DCL patients with therapeutic failure: a proof of concept.

Maritza Padrón-Nieves1, Claudia Machuca, Emilia Díaz, Paulo Cotrim, Noris Rodriguez, Alicia Ponte-Sucre.   

Abstract

Besides infection with drug-resistant parasites, therapeutic failure in leishmaniasis may be caused by altered drug pharmacokinetics, re-infection, and host immunologic compromise. Our aim has been to evaluate if relapses that occur in patients suffering from diffuse cutaneous leishmaniasis (DCL) associate with changes in the fitness of infecting organisms. Therefore, in isolates from patients suffering DCL, we correlated glucose uptake and plasma membrane potential and compared the results with those obtained from reference strains. The data demonstrate that Leishmania parasites causing DCL incorporate glucose at an efficient rate, albeit without significant changes in the plasma membrane potential as their corresponding reference strains. The isolate that did not change its accumulation rate of glucose compared to its reference strain expressed a less polarized membrane potential that was insensitive to mitochondrial inhibitors, suggesting a metabolic dysfunction that may result in glycolysis being the main source of ATP. The results constitute a proof of concept that indicates that parasites causing DCL adapted well to drug pressure and expressed an increased fitness. That is, that in Leishmania mexicana and Leishmania amazonensis, parasites isolated from DCL patients, a strong modification of the parasite physiology might occur. As consequences, the parasites adapted well to drug pressure, increased their fitness, and they had an efficient glucose uptake rate albeit not significant changes in membrane potential as their corresponding reference strains. Further validation of the concepts herein established and whether or not the third isolate corresponds with a drug-resistant phenotype need to be demonstrated at the genetic level.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24671239     DOI: 10.1007/s00436-014-3862-4

Source DB:  PubMed          Journal:  Parasitol Res        ISSN: 0932-0113            Impact factor:   2.289


  30 in total

1.  Metabolic adaptations of Leishmania donovani in relation to differentiation, drug resistance, and drug pressure.

Authors:  Maya Berg; Manu Vanaerschot; Andris Jankevics; Bart Cuypers; Ilse Maes; Sandip Mukherjee; Basudha Khanal; Suman Rijal; Syamal Roy; Fred Opperdoes; Rainer Breitling; Jean-Claude Dujardin
Journal:  Mol Microbiol       Date:  2013-09-11       Impact factor: 3.501

2.  Increased metacyclogenesis of antimony-resistant Leishmania donovani clinical lines.

Authors:  M Ouakad; M Vanaerschot; S Rijal; S Sundar; N Speybroeck; L Kestens; L Boel; S De Doncker; I Maes; S Decuypere; J-C Dujardin
Journal:  Parasitology       Date:  2011-08-08       Impact factor: 3.234

3.  Resistance to pentamidine in Leishmania mexicana involves exclusion of the drug from the mitochondrion.

Authors:  Mireille Basselin; Hubert Denise; Graham H Coombs; Michael P Barrett
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

4.  Characterization of the redox components of transplasma membrane electron transport system from Leishmania donovani promastigotes.

Authors:  Tanmoy Bera; Kuruba Lakshman; Debiprasad Ghanteswari; Sabita Pal; Dharmalingam Sudhahar; Md Nurul Islam; Nihar Ranjan Bhuyan; Pradeep Das
Journal:  Biochim Biophys Acta       Date:  2005-06-22

5.  Linking in vitro and in vivo survival of clinical Leishmania donovani strains.

Authors:  Manu Vanaerschot; Ilse Maes; Meriem Ouakad; Vanessa Adaui; Louis Maes; Simonne De Doncker; Suman Rijal; François Chappuis; Jean-Claude Dujardin; Saskia Decuypere
Journal:  PLoS One       Date:  2010-08-17       Impact factor: 3.240

6.  Functional genetic identification of PRP1, an ABC transporter superfamily member conferring pentamidine resistance in Leishmania major.

Authors:  Adriano C Coelho; Stephen M Beverley; Paulo C Cotrim
Journal:  Mol Biochem Parasitol       Date:  2003-08-31       Impact factor: 1.759

7.  The efficacy of pentamidine combined with allopurinol and immunotherapy for the treatment of patients with diffuse cutaneous leishmaniasis.

Authors:  I Becker; P Volkow; O Velasco-Castrejon; N Salaiza-Suazo; M Berzunza-Cruz; J S Dominguez; A Morales-Vargas; A Ruiz-Remigio; R Perez-Montfort
Journal:  Parasitol Res       Date:  1999-03       Impact factor: 2.289

Review 8.  Drug-resistant microorganisms with a higher fitness--can medicines boost pathogens?

Authors:  Manu Vanaerschot; Saskia Decuypere; Maya Berg; Syamal Roy; Jean-Claude Dujardin
Journal:  Crit Rev Microbiol       Date:  2012-09-06       Impact factor: 7.624

9.  Antimonial resistance in Leishmania donovani is associated with increased in vivo parasite burden.

Authors:  Manu Vanaerschot; Simonne De Doncker; Suman Rijal; Louis Maes; Jean-Claude Dujardin; Saskia Decuypere
Journal:  PLoS One       Date:  2011-08-01       Impact factor: 3.240

10.  Identification, expression and characterisation of a Babesia bovis hexose transporter.

Authors:  Elvira T Derbyshire; Frits J Franssen; Erik de Vries; Christophe Morin; Charles J Woodrow; Sanjeev Krishna; Henry M Staines
Journal:  Mol Biochem Parasitol       Date:  2008-06-27       Impact factor: 1.759

View more
  1 in total

1.  Leishmanicidal Activity of Betulin Derivatives in Leishmania amazonensis; Effect on Plasma and Mitochondrial Membrane Potential, and Macrophage Nitric Oxide and Superoxide Production.

Authors:  Wilmer Alcazar; Sami Alakurtti; Maritza Padrón-Nieves; Maija Liisa Tuononen; Noris Rodríguez; Jari Yli-Kauhaluoma; Alicia Ponte-Sucre
Journal:  Microorganisms       Date:  2021-02-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.